TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01389102
Drug: Estradiol transdermal spray, two 90 μL sprays
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estradiol transdermal spray, two 90 μL spray applied to adjacent non-overlapping areas on 1 inner forearm daily for 12 weeks using a blinded applicator
Study: NCT00133497
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mL of saline placebo.
Study: NCT00721305
Drug: Lovastatin
Normalized name: Lovastatin
DrugBank: Lovastatin (DB00227)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lovastatin 40 mg daily (2 tablets of 20 mg each, p.o.), during twelve months until the end of the study, or before the end of the study if any AIDS defining disease or toxicity appear
Study: NCT00002470
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01371162
Drug: RO5428029
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple ascending doses
Study: NCT01371162
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: multiple doses
Study: NCT00978198
Drug: ASP1517
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT00978198
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT03610724
Drug: Bridging Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-treatment phase could also include bridging therapy of investigator's choice
Study: NCT04659421
Drug: combined therapy with rh-ES and CV
Approvals — FDA: no, EMA: no, PMDA: no
Description: All the patients receive combined therapy with recombinant human endostatin and traditional weekly CV regimen.~Carboplatin is administered at a dose of 220 mg/m2. Vincristine is administered at a dose of 1.5 mg/m2 (maximum dose 2 mg). Recombinant human endostatin (rh-ES) is administrated at a dose of 15mg daily, for 14 consecutive days every 3 weeks.
Study: NCT01535859
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet daily for 8 days.
Study: NCT02549651
Drug: MEDI4736
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEDI4736 is an anti-PD-L1 monoclonal antibody (MAb) administered via intravenous infusion
Study: NCT03422419
Drug: Heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The choice of the anticoagulant medication in terms of duration and dose will be determined by the treating physician.
Study: NCT02549651
Drug: AZD9150
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD9150 is an antisense oligonucleotide (ASO) administered via intravenous infusion
Study: NCT03136380
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive visually matching danirixin placebo tablets. It will be administered with 240 mL of water.
Study: NCT00742248
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pMDI/DPI 1 dose in the morning and 1 dose in the evening
Study: NCT02536313
Drug: SOF/VEL/VOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400/100/100 mg FDC tablet administered orally once daily with food
Study: NCT01470170
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal Saline (placebo comparator) was given in equivalent amount of alfentanil dosage in each arm, for double blinded purpose.
Study: NCT04647877
Drug: phenytoin cream
Normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phenytoin cream to be applied on the neuropathic pain area
Study: NCT04993040
Drug: Oraxol
Normalized name: doxycycline hyclate Oral Capsule [Oraxyl]
Approvals — FDA: no, EMA: no, PMDA: no
Description: * HM30181 methanesulfonate monohydrate~* Oral paclitaxel capsules
Study: NCT02124278
Drug: PUL-042 Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01157754
Drug: levonorgestrel and ethynilestradiol
Normalized name: levonorgestrel and ethinylestradiol
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04116528
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine or Placebo orally dissolving tablet
Study: NCT02691572
Drug: Intrathecal fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl 15 µg will be administered in the subarachnoid space.
Study: NCT02691572
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV ketorolac 30 mg/8 h starting at the end of surgery.
Study: NCT02420977
Drug: Pelvic DCFPyL PET-MRI fusion or PET/MRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Pelvic DCFPyL PET-MRI fusion or PET/MRI compared before and after 2-3 months of ADT~* Pelvic DCFPyL PET-MRI fusion or PET/MRI compared before and after 2-3 months
Study: NCT03420339
Drug: Stimulant
Normalized name: Stimulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: The stimulants used must meet FDA dosage guidelines for age.
Study: NCT00912002
Drug: MK-0941
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of 40 mg of \[14C\]MK-0941 (160 µCi), taken orally as eight 5-mg capsules
Study: NCT01020734
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04753710
Drug: Ocular gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Instillation
Study: NCT03625050
Drug: Usual care(Celecoxib and esomeprazole)
Normalized name: amlodipine and celecoxib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care therapy (UC, Celecoxib 200mg, qd and esomeprazole 20mg, qd), 4 weeks~Usual care consists of physical therapy, CP based medications and patients education. Physical therapy consists of meridian muscle interferential current electricity (or meridian transcutaneous electricity) and hot pack (or infrared lamp).
Study: NCT02090413
Drug: acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: enteric-coated capsule
Study: NCT02090413
Drug: ASA-Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matched placebo
Study: NCT01045798
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to caspofungin (normal saline) on Day 1 followed by placebo daily for at least 6 additional days (maximum duration study therapy is 14 days)
Study: NCT03594552
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose placebo (oral tablet)
Study: NCT01792804
Drug: Clindamycin
Normalized name: Clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: study drug 2
Study: NCT04209543
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral tablet: administered orally once daily
Study: NCT03514771
Drug: oral isotretinoin
Normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral isotretinoin
Study: NCT02419937
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline injection
Study: NCT00004907
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02670824
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal Saline
Study: NCT03697720
Drug: Naproxen
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will take naproxen 500mg BID before and for the first 3 days of their period.
Study: NCT04083846
Drug: Reference drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: D744 Cap. 1 Cap., single oral administration under fed condition
Study: NCT04083846
Drug: Test drug 1
Normalized name: URINE TEST DRUGS
Approvals — FDA: no, EMA: no, PMDA: no
Description: CKD-385 64 mg formulation I Tab. 1 Tab., single oral administration under fed condition
Study: NCT04083846
Drug: Test drug 2
Normalized name: URINE TEST DRUGS
Approvals — FDA: no, EMA: no, PMDA: no
Description: CKD-385 64 mg formulation II Tab. 1 Tab., single oral administration under fed condition
Study: NCT01199588
Drug: Nexagon® Low Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly, topical application of Nexagon® low dose used with compression dressings.
Study: NCT02175238
Drug: BI 691751 after high fat breakfast
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose BI 691751 after a standardised high fat breakfast
Study: NCT02914600
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet administered orally once a day
Study: NCT00354198
Drug: corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous methylprednisolone (15 mg/kg/day or a maximum of 1 g/day) x 3 days + oral prednisolone (0.5-1.0 mg/kg/day) for 27 days\] x 3 courses
Study: NCT03717350
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100ml of sodium chloride 0.9% within 15 minutes intravenously once
Study: NCT00659321
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 weeks treatment with placebo
Study: NCT02458469
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One placebo pill before bed-time
Study: NCT02916290
Drug: Fuzhenghuayu
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01813006
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02171637
Drug: BIBW 2992
Approvals — FDA: no, EMA: no, PMDA: no
Description: escalating doses
Study: NCT01586611
Drug: 5FU, leucovorin, oxaliplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxaliplatin 100 mg/m2 IV day 1 Leucovorin 400 mg/m2 IV day 1 5-FUl 400 mg/m2 IV day 1 5-FU 2400 mg/m2 IV continuous infusion over 46 hours starting day 1
Study: NCT03314298
Drug: testosterone anastrozole
Normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: subcutaneous testosterone and anastrozole
Study: NCT00004562
Drug: Platelet inhibitors
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive platelet inhibitors.
Study: NCT00567762
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo eye drops
Study: NCT02964260
Drug: Embolic agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipiodol/Gelatin sponge/PVA/Blank microspheres
Study: NCT04321850
Drug: Zinc Sulfate 50 Mg Tab
Normalized name: zinc sulfate 50 MG
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The tablets were manufactured specifically for this study.
Study: NCT04321850
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: The tablets were manufactured specifically for this study.
Study: NCT02469805
Drug: Choriomon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of 10000 IU of human chorionic gonadotropin (hCG; Choriomon®, IBSA) when at least 2 follicles measuring 18 mm are observed during vaginal ultrasound and is associated with serum E2 of 500-3000 Pg/mL.
Study: NCT03527147
Drug: AZD5153
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD5153 will be administered orally once per day (qd).
Study: NCT02967159
Drug: AZD7594
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment B: AZD7594 440 μg via DPI
Study: NCT00861120
Drug: Pegylated liposomal doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg/m2 on day 1 of a 28 days cycle
Study: NCT00393029
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 60 mg/kg/day x 2 days intravenously in 250ml dextrose 5% in water (D5W) with mesna 15 mg/kg/day x 2 days over 1 hour.
Study: NCT00909402
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tablets, Oral, 1000 mg/m², twice a day (BID), 14 days per cycle, until discontinuation from study
Study: NCT02023606
Drug: SPN-810M
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04737408
Drug: Rosuvastatin 40mg
Normalized name: ROSUVASTATIN 40MG CAP,SPRINKLE
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rosuvastatin 40 mg
Study: NCT02100228
Drug: Parenteral heparin and/or oral Vitamin K antagonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral heparin and/or locally used oral Vitamin K antagonist e.g. warfarin (excludes other novel oral anticoagulants)
Study: NCT02024932
Drug: BVS857
Approvals — FDA: no, EMA: no, PMDA: no
Description: BVS857 lyophilisate in vial; the lyophilisate was reconstituted with sterile water for injection, diluted as appropriate, and administered either i.v. or s.c..
Study: NCT02024932
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo lyophilisate in vial; the lyophilisate was reconstituted with sterile water for injection, diluted as appropriate, and administered either i.v. or s.c..
Study: NCT02320669
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus of Placebo followed by infusion for 48 hours
Study: NCT04611789
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered subcutaneously
Study: NCT02235662
Drug: TFV IVR
Normalized name: Ivra
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03707912
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration.
Study: NCT04380337
Drug: FOLFOXIRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy regimen of Oxaliplatin 85mg/m2 , Leucovorin 400 mg/m2 , Irinotecan 165mg/m2 , 5-Fluorouracil
Study: NCT04380337
Drug: FOLFOX regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy regimen of Oxaliplatin 85mg/m2, Leucovorin 400 mg/m2, 5-Fluorouracil 2400mg/m2
Study: NCT04380337
Drug: XELOX
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chemotherapy regimen of Oxaliplatin 130 mg/m2, Capecitabine 1000mg/m2
Study: NCT03547583
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo and sham up-titration at weeks 2, 4, and 6
Study: NCT00172133
Drug: ALX1-11 (drug)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mcg PTH(1-84) injected subcutaneously daily in either the thrigh and abdomen.
Study: NCT03348423
Drug: DEX-IN
Approvals — FDA: no, EMA: no, PMDA: no
Description: IN Dexmedetomidine + IV placebo
Study: NCT03348423
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IN Placebo + IV Fentanyl
Study: NCT03348423
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IN Placebo + IV Placebo
Study: NCT02817841
Drug: 15 mg E4/3 mg DRSP
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg estetrol and 3 mg drospirenone tablets administered once daily for 13 consecutive cycles following a 24/4-day regimen, i.e. one 15 mg E4/3 mg DRSP active tablet per day for 24 consecutive days followed by one placebo tablet per day for 4 consecutive days.
Study: NCT03952559
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT03952559
Drug: Topical corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as standard-of-care
Study: NCT01860105
Drug: MDCO-157
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous administration
Study: NCT00003114
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral cyclophosphamide on days 22-31. The course is repeated every 6 weeks. A complete or partial response after 1 course of treatment receive two additional courses, but lomustine is omitted in the second course.
Study: NCT03744364
Drug: Dinoprostone 10mg
Normalized name: DINOPROSTONE 10MG INSERT,VAG
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: To determine efficacy and safety of 'Dinoprostone 10mg' vaginal insert for induction of labor.
Study: NCT01616381
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for sildenafil 40mg x 3 daily
Study: NCT03975387
Drug: ASTX295
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASTX295 orally for 28-day cycle continuous or on an intermittent dosing schedule.
Study: NCT00833794
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03072992
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo i.v. solution, once weekly for 12 weeks
Study: NCT03214510
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given via thoracic epidural catheter
Study: NCT02080247
Drug: Skin care regimen with Calmoseptine ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Application of Calmoseptine Ointment for 6 days will be applied on the affected area that will be calculated by multiplying the longest portion of the affected area measured in a head to toe orientation by the widest portion of the affected area measured from side to side(in Centimeters).
Study: NCT02080247
Drug: Skin care regimen with Destin ointment
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Application of Destin for 6 days will be applied on the affected area that will be calculated by multiplying the longest portion of the affected area measured in a head to toe orientation by the widest portion of the affected area measured from side to side(in Centimeters). Patients will receive treatment with Destin Maximum Strength 40% Zinc Oxide Diaper Rash Paste (Destin) for 6 days as part of a structured skin care regimen.
Study: NCT00434421
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo was administered only as the first dose (e.g., representing no Glycerinated German Cockroach bioequivalent allergy units) during the initial 1-day, 8-dose escalation, otherwise referred to as the Preliminary Dosing Visit. Refer to the Glycerinated German cockroach allergenic extract treatment for more details. Route of administration: sublingual-oral route.
Study: NCT02925702
Drug: Radium 223 55mBq/Kg every 4 weeks intravenously
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radium-223 55kBq/kg infusion IV every 4 weeks
Study: NCT02409316
Drug: [18F]FES
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[18F\]FES PET/CT scan
Study: NCT02489526
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group will receive the corresponding amount of placebo.
Study: NCT00768326
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study Part A, B, C, D and E:~Placebo; orally, film-coated tablets, once daily, 8 weeks
Study: NCT00269776
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment C: Three OROS placebo tablets once daily + 1 placebo capsule 3x times/day for 7 days. Each patient will be randomized to 1 of 9 treatment sequences each consisting of 3 7-day treatment periods of Treatment A, B, and C.
Study: NCT01925937
Drug: placebo for coenzyme Q10
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02246621
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT02111044
Drug: ITF2984 500 mcg
Approvals — FDA: no, EMA: no, PMDA: no
Description: ITF2984 500 mcg sc b.i.d for 4 weeks
Study: NCT02111044
Drug: ITF2984 1000 mcg
Approvals — FDA: no, EMA: no, PMDA: no
Description: ITF2984 1000 mcg sc b.i.d for 4 weeks
Study: NCT02111044
Drug: ITF2984 2000 mcg
Approvals — FDA: no, EMA: no, PMDA: no
Description: ITF2984 2000 mcg sc b.i.d for 4 weeks
Study: NCT01069939
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, capsule, 72 weeks
Study: NCT00750815
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Enroll patients into 4 different dose levels. The dose of Cyclophosphamide they receive will depend on how many patients have been treated.
Study: NCT00853320
Drug: Roxicodone™ tablet 15 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roxicodone™ tablet 15 mg, single dose fasting
Study: NCT00653614
Drug: E2/DRSP (BAY 86-4891) dose 1 (SH T04984E)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose administration of E2 + DRSP as a tablet
Study: NCT00653614
Drug: E2/DRSP (BAY 86-4891) dose 2 (80458739)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose administration of E2 + DRSP as a tablet
Study: NCT00653614
Drug: E2/DRSP (BAY 86-4891) dose 3 (80458755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose administration of E2 + DRSP as a tablet
Study: NCT00653614
Drug: E2/DRSP (BAY 86-4891) dose 4 (80458720)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose administration of E2 + DRSP as a tablet
Study: NCT00653614
Drug: E2/DRSP (BAY 86-4891) dose 5 (80458712)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose administration of E2 + DRSP as a tablet
Study: NCT00653614
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administration in each arm
Study: NCT01012934
Drug: Fosamax Tablets, 70 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 x 70 mg, single-dose fasting
Study: NCT02657915
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as specified in the treatment arm.
Study: NCT02657915
Drug: BIIB033 100mg/Kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as specified in the treatment arm.
Study: NCT02332148
Drug: Placebo for 3VM1001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical cream placebo for 3VM1001; cream without 3VM1001
Study: NCT00406068
Drug: Mycobacterial cell wall-DNA complex
Normalized name: Toxoplasma gondii DNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg MCC, intravesical - Induction Phase (6 weekly intravesical instillations) and Maintenance Phase (3 weekly instillations at months 3, 6, 12, 18 and 24).
Study: NCT01591785
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo ointment for 5 days AND clobetasol propionate foam for 14 days
Study: NCT00849901
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules identical in appearance, color, taste and smell to study drug, orally (PO), once daily (QD). Dose: placebo, 6 capsules, QD for 10 weeks
Study: NCT00849901
Drug: fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10-40 milligram (mg), PO, QD, for up to 38 weeks
Study: NCT01541891
Drug: Active Comparator: SYSTANE ® Ophthalmic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile solution containing polyethylene glycol 400, propylene glycol, hydroxypropyl-guar, boric acid, calcium chloride, magnesium chloride, potassium chloride, sodium chloride, zinc chloride and polyquad (polidronium chloride) 0,001%. four times per day (c/6 hours) during 60 days.